Product Images Clopidogrel Bisulfate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Clopidogrel Bisulfate NDC 62034-015 by Blenheim Pharmacal, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label Graphic-Clopidogrel 75mg 100s - LABEL CLOPIDOGRELTABS 75MG BPI(62034 015 77) APOTEX(60505 0253 3) REV1

Label Graphic-Clopidogrel 75mg 100s - LABEL CLOPIDOGRELTABS 75MG BPI(62034 015 77) APOTEX(60505 0253 3) REV1

This is a description of a medication called Clopidogrel, which comes in tablet form, with a dosage of 75mg. The package contains one unit dose of the tablets, and each coated tablet contains 97.875mg of Clopidogrel Bisulfate, equivalent to 75mg of Clopidogrel Base. The medication is meant to be kept out of reach of children and stored at a controlled temperature of 15 to 30 degrees Celsius. The package includes an instructional leaflet for proper usage. The medication is produced by Apotex, and the package has a National Drug Code number of 62034-015-77.*

clopiodgrel-01 - image 01

clopiodgrel-01 - image 01

figure-01 - image 02

figure-01 - image 02

Figure 1 shows the effect of co-administering proton pump inhibitors (PPls) on exposure to Clopidogrel Active Metabolite after multiple doses of Clopidogrel 75 mg. The graph displays mean and 90% confidence intervals for the effect on active metabolite AUC of co-administration with different PPls such as Destansoprazole, Pustoprzsle and Omepnzole. The change in relative to Clopidogrel administered alone is also shown.*

figure2 - image 03

figure2 - image 03

Figure 3 - image 04

Figure 3 - image 04

figure4 - image 05

figure4 - image 05

The text provides a graph, figure 4, that shows the cumulative event rates for death in the COMMIT Study™. No further information is available.*

figure5 - image 06

figure5 - image 06

The text describes a figure which shows the cumulative event rates for the combined endpoint of re-infraction, stroke, or death in a study referred to as the COMMIT study. The figure includes a chart with the number of events and percentages of individuals who experienced the combined endpoint based on days since randomization. Some additional information about specific numbers and drugs used in the study is also included. The figure may be related to cardiology or cardiovascular research.*

figure6 - image 07

figure6 - image 07

This is a figure showing the effects of adding Clopidogrel to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups. The data is categorized by Baseline Svens Heterogeneity and Prognostic Index. There are also statistics on Fibrinolytic agent given, Metoprolol allocation, and Proportions. The figure also includes information on Three similar-sized prognostic index groups.*

figure7 - image 08

figure7 - image 08

Figure 8 - image 09

Figure 8 - image 09

The text provides a figure and data from the CAPRIE study showing the event rate (%) for fatal or non-fatal vascular events. It is difficult to determine the exact meaning without additional context or clearer images.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.